Literature DB >> 33208459

Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile.

Jaclyn C Law1, Wan Hon Koh1,2, Patrick Budylowski2,3, Jonah Lin1, FengYun Yue2, Kento T Abe4,5, Bhavisha Rathod4, Melanie Girard1, Zhijie Li5, James M Rini5,6, Samira Mubareka7,8, Allison McGeer4,8, Adrienne K Chan7,9, Anne-Claude Gingras4,5, Tania H Watts10, Mario A Ostrowski1,2,11.   

Abstract

There is a pressing need for an in-depth understanding of immunity to SARS-CoV-2. In this study, we investigated human T cell recall responses to fully glycosylated spike trimer, recombinant N protein, as well as to S, N, M, and E peptide pools in the early convalescent phase and compared them with influenza-specific memory responses from the same donors. All subjects showed SARS-CoV-2-specific T cell responses to at least one Ag. Both SARS-CoV-2-specific and influenza-specific CD4+ T cell responses were predominantly of the central memory phenotype; however SARS-CoV-2-specific CD4+ T cells exhibited a lower IFN-γ to TNF ratio compared with influenza-specific memory responses from the same donors, independent of disease severity. SARS-CoV-2-specific T cells were less multifunctional than influenza-specific T cells, particularly in severe cases, potentially suggesting exhaustion. Most SARS-CoV-2-convalescent subjects also produced IFN-γ in response to seasonal OC43 S protein. We observed granzyme B+/IFN-γ+, CD4+, and CD8+ proliferative responses to peptide pools in most individuals, with CD4+ T cell responses predominating over CD8+ T cell responses. Peripheral T follicular helper (pTfh) responses to S or N strongly correlated with serum neutralization assays as well as receptor binding domain-specific IgA; however, the frequency of pTfh responses to SARS-CoV-2 was lower than the frequency of pTfh responses to influenza virus. Overall, T cell responses to SARS-CoV-2 are robust; however, CD4+ Th1 responses predominate over CD8+ T cell responses, have a more inflammatory profile, and have a weaker pTfh response than the response to influenza virus within the same donors, potentially contributing to COVID-19 disease.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33208459      PMCID: PMC7750861          DOI: 10.4049/jimmunol.2001067

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure.

Authors:  Jing He; Louis M Tsai; Yew Ann Leong; Xin Hu; Cindy S Ma; Nina Chevalier; Xiaolin Sun; Kirsten Vandenberg; Steve Rockman; Yan Ding; Lei Zhu; Wei Wei; Changqi Wang; Alexander Karnowski; Gabrielle T Belz; Joanna R Ghali; Matthew C Cook; D Sean Riminton; André Veillette; Pamela L Schwartzberg; Fabienne Mackay; Robert Brink; Stuart G Tangye; Carola G Vinuesa; Charles R Mackay; Zhanguo Li; Di Yu
Journal:  Immunity       Date:  2013-10-17       Impact factor: 31.745

2.  Simple piggyBac transposon-based mammalian cell expression system for inducible protein production.

Authors:  Zhijie Li; Iacovos P Michael; Dongxia Zhou; Andras Nagy; James M Rini
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-08       Impact factor: 11.205

Review 3.  Suppression of antigen presentation by IL-10.

Authors:  Sharad K Mittal; Paul A Roche
Journal:  Curr Opin Immunol       Date:  2015-01-16       Impact factor: 7.486

4.  Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination.

Authors:  Lisa E Wagar; Laura Rosella; Natasha Crowcroft; Beth Lowcock; Paulina C Drohomyrecky; Julie Foisy; Jonathan Gubbay; Anu Rebbapragada; Anne-Luise Winter; Camille Achonu; Brian J Ward; Tania H Watts
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

5.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.

Authors:  Daniela Weiskopf; Katharina S Schmitz; Alessandro Sette; Rory D de Vries; Matthijs P Raadsen; Alba Grifoni; Nisreen M A Okba; Henrik Endeman; Johannes P C van den Akker; Richard Molenkamp; Marion P G Koopmans; Eric C M van Gorp; Bart L Haagmans; Rik L de Swart
Journal:  Sci Immunol       Date:  2020-06-26

Review 6.  Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.

Authors:  Alessandro Sette; Shane Crotty
Journal:  Nat Rev Immunol       Date:  2020-08       Impact factor: 53.106

7.  Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.

Authors:  Sara De Biasi; Marianna Meschiari; Lara Gibellini; Caterina Bellinazzi; Rebecca Borella; Lucia Fidanza; Licia Gozzi; Anna Iannone; Domenico Lo Tartaro; Marco Mattioli; Annamaria Paolini; Marianna Menozzi; Jovana Milić; Giacomo Franceschi; Riccardo Fantini; Roberto Tonelli; Marco Sita; Mario Sarti; Tommaso Trenti; Lucio Brugioni; Luca Cicchetti; Fabio Facchinetti; Antonello Pietrangelo; Enrico Clini; Massimo Girardis; Giovanni Guaraldi; Cristina Mussini; Andrea Cossarizza
Journal:  Nat Commun       Date:  2020-07-06       Impact factor: 14.919

8.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques.

Authors:  Abishek Chandrashekar; Jinyan Liu; Amanda J Martinot; Katherine McMahan; Noe B Mercado; Lauren Peter; Lisa H Tostanoski; Jingyou Yu; Zoltan Maliga; Michael Nekorchuk; Kathleen Busman-Sahay; Margaret Terry; Linda M Wrijil; Sarah Ducat; David R Martinez; Caroline Atyeo; Stephanie Fischinger; John S Burke; Matthew D Slein; Laurent Pessaint; Alex Van Ry; Jack Greenhouse; Tammy Taylor; Kelvin Blade; Anthony Cook; Brad Finneyfrock; Renita Brown; Elyse Teow; Jason Velasco; Roland Zahn; Frank Wegmann; Peter Abbink; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Xuan He; Catherine Jacob-Dolan; Nicole Kordana; Zhenfeng Li; Michelle A Lifton; Shant H Mahrokhian; Lori F Maxfield; Ramya Nityanandam; Joseph P Nkolola; Aaron G Schmidt; Andrew D Miller; Ralph S Baric; Galit Alter; Peter K Sorger; Jacob D Estes; Hanne Andersen; Mark G Lewis; Dan H Barouch
Journal:  Science       Date:  2020-05-20       Impact factor: 47.728

9.  Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.

Authors:  Runhong Zhou; Kelvin Kai-Wang To; Yik-Chun Wong; Li Liu; Biao Zhou; Xin Li; Haode Huang; Yufei Mo; Tsz-Yat Luk; Thomas Tsz-Kan Lau; Pauline Yeung; Wai-Ming Chan; Alan Ka-Lun Wu; Kwok-Cheung Lung; Owen Tak-Yin Tsang; Wai-Shing Leung; Ivan Fan-Ngai Hung; Kwok-Yung Yuen; Zhiwei Chen
Journal:  Immunity       Date:  2020-08-04       Impact factor: 31.745

10.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Authors:  Alessandro Sette; Daniela Weiskopf; Jose Mateus; Alba Grifoni; Alison Tarke; John Sidney; Sydney I Ramirez; Jennifer M Dan; Zoe C Burger; Stephen A Rawlings; Davey M Smith; Elizabeth Phillips; Simon Mallal; Marshall Lammers; Paul Rubiro; Lorenzo Quiambao; Aaron Sutherland; Esther Dawen Yu; Ricardo da Silva Antunes; Jason Greenbaum; April Frazier; Alena J Markmann; Lakshmanane Premkumar; Aravinda de Silva; Bjoern Peters; Shane Crotty
Journal:  Science       Date:  2020-08-04       Impact factor: 47.728

View more
  8 in total

1.  Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases.

Authors:  Roya M Dayam; Jaclyn C Law; Rogier L Goetgebuer; Gary Yc Chao; Kento T Abe; Mitchell Sutton; Naomi Finkelstein; Joanne M Stempak; Daniel Pereira; David Croitoru; Lily Acheampong; Saima Rizwan; Klaudia Rymaszewski; Raquel Milgrom; Darshini Ganatra; Nathalia V Batista; Melanie Girard; Irene Lau; Ryan Law; Michelle W Cheung; Bhavisha Rathod; Julia Kitaygorodsky; Reuben Samson; Queenie Hu; W Rod Hardy; Nigil Haroon; Robert D Inman; Vincent Piguet; Vinod Chandran; Mark S Silverberg; Anne-Claude Gingras; Tania H Watts
Journal:  JCI Insight       Date:  2022-06-08

Review 2.  Immune profiling of COVID-19: preliminary findings and implications for the pandemic.

Authors:  Holden T Maecker
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

3.  Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients.

Authors:  Victor H Ferreira; Tina Marinelli; Matthew Ierullo; Terrance Ku; Victoria G Hall; Beata Majchrzak-Kita; Vathany Kulasingam; Atul Humar; Deepali Kumar
Journal:  J Infect Dis       Date:  2021-12-01       Impact factor: 5.226

4.  Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study.

Authors:  Victoria G Hall; Victor Ferreira; Deepali Kumar; Atul Humar
Journal:  Transpl Infect Dis       Date:  2021-11-01

5.  Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2.

Authors:  Joshua M Francis; Del Leistritz-Edwards; Augustine Dunn; Christina Tarr; Jesse Lehman; Conor Dempsey; Andrew Hamel; Violeta Rayon; Gang Liu; Yuntong Wang; Marcos Wille; Melissa Durkin; Kane Hadley; Aswathy Sheena; Benjamin Roscoe; Mark Ng; Graham Rockwell; Margaret Manto; Elizabeth Gienger; Joshua Nickerson; Amir Moarefi; Michael Noble; Thomas Malia; Philip D Bardwell; William Gordon; Joanna Swain; Mojca Skoberne; Karsten Sauer; Tim Harris; Ananda W Goldrath; Alex K Shalek; Anthony J Coyle; Christophe Benoist; Daniel C Pregibon
Journal:  Sci Immunol       Date:  2022-01-21

6.  SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients.

Authors:  Laís Teodoro da Silva; Marina Mazzilli Ortega; Bruna Tiaki Tiyo; Isabelle Freire Tabosa Viana; Tayná Evily de Lima; Tania Regina Tozetto-Mendoza; Luanda Mara da Silva Oliveira; Franciane Mouradian Emidio Teixeira; Roberto Dias Lins; Alexandre de Almeida; Maria Cassia Mendes-Correa; Alberto Jose da Silva Duarte; Telma Miyuki Oshiro
Journal:  Clinics (Sao Paulo)       Date:  2021-12-06       Impact factor: 2.365

7.  Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.

Authors:  Jun Liu; Patrick Budylowski; Reuben Samson; Bryan D Griffin; Giorgi Babuadze; Bhavisha Rathod; Karen Colwill; Jumai A Abioye; Jordan A Schwartz; Ryan Law; Lily Yip; Sang Kyun Ahn; Serena Chau; Maedeh Naghibosadat; Yuko Arita; Queenie Hu; Feng Yun Yue; Arinjay Banerjee; W Rod Hardy; Karen Mossman; Samira Mubareka; Robert A Kozak; Michael S Pollanen; Natalia Martin Orozco; Anne-Claude Gingras; Eric G Marcusson; Mario A Ostrowski
Journal:  Sci Adv       Date:  2022-01-19       Impact factor: 14.136

8.  Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).

Authors:  Sabrina Jotschke; Susann Schulze; Nadja Jaekel; Beatrice Ludwig-Kraus; Robby Engelmann; Frank Bernhard Kraus; Christina Zahn; Nicole Nedlitz; Gabriele Prange-Krex; Johannes Mohm; Bettina Peuser; Maik Schwarz; Claudia Spohn; Timo Behlendorf; Mascha Binder; Christian Junghanss; Sebastian Böttcher; Haifa Kathrin Al-Ali
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.